NICE stock: Citizens JMP cuts target but keeps outperform rating

Citizens JMP lowered its price target for NICE on Thursday, November 5, from 170 US dollars to 158 US dollars while maintaining a market outperform rating, according to MarketBeat. The revision adds a more cautious broker view after NICE's third-quarter results, even as the rating remained positive.

Broker Target Moves Lower

MarketBeat said Citizens JMP's new target still represented substantial upside relative to the share price referenced in its report. The broker's action was part of a mixed analyst picture: MarketBeat reported nine Buy ratings and seven Hold ratings, producing a Moderate Buy consensus and an average price target of 130.86 US dollars.

Other recent broker actions cited by MarketBeat included Citigroup maintaining a market outperform view and Oppenheimer upgrading NICE to outperform with a 150 US dollar target. The range of targets shows that analysts remain constructive on the company's long-term opportunity while differing on how quickly growth and profitability can improve.

Quarterly Beat Meets Profit Pressure

NICE reported third-quarter revenue of 790.7 million US dollars, up 8 percent from a year earlier, while adjusted earnings per share reached 2.84 US dollars, above the 2.78 US dollar consensus cited by MarketBeat. Earnings nevertheless declined from 3.18 US dollars in the year-earlier quarter, leaving investors to weigh revenue growth against profit conversion.

Management also raised its full-year adjusted earnings outlook after the quarter, while the company announced plans to reduce its global workforce by about 5 percent. Those measures place execution and efficiency alongside AI-led growth as key issues for the NICE stock outlook.

Current Trading Context

NICE stock traded at 85.50 euros on Lang & Schwarz at 11:39 CET on Wednesday, November 11, 2026.

For the broader market setting, investors can follow the TA-35 index.

Further developments in broker assessments, AI adoption and operating efficiency will shape the next phase for the NICE stock.